Table 2.

Risk for all-cause death, CVE, sudden death, stroke, and MI by baseline PF4-H-ABs

ParameterPatients with
Negative PF4-H-AB Status (n = 1005)Positive PF4-H-AB Status (n = 231)
All-cause death
    no. of events during study486119
    Kaplan-Meier estimate (95% CI)a0.49 (0.45 to 0.52)0.54 (0.47 to 0.62)
    adjusted HR (95% CI; P)bc1.15 (0.94 to 1.41; 0.18)
    adjusted HR (95% CI; P)b with PF4-H-ABs as continuous variable1.12 (0.95 to 1.32; 0.19)
CVE (MI, cardiac death, and stroke)
    no. of events during study37288
    Kaplan-Meier estimate (95% CI)a0.43 (0.39 to 0.47)0.44 (0.36 to 0.52)
    adjusted HR (95% CI; P)bc1.09 (0.86 to 1.38; 0.48)
    adjusted HR (95% CI; P)b with PF4-H-ABs as continuous variable1.08 (0.89 to 1.30; 0.44)
Sudden death
    no. of events during study12435
    Kaplan-Meier estimate (95% CI)a0.16 (0.13 to 0.19)0.19 (0.12 to 0.25)
    adjusted HR (95% CI; P)bc1.39 (0.95 to 2.03; 0.09)
    adjusted HR (95% CI; P)b with PF4-H-ABs as continuous variable1.41 (1.03 to 1.92; 0.03)
Stroke
    no. of events during study8215
    Kaplan-Meier estimate (95% CI)a0.10 (0.08 to 0.13)0.08 (0.04 to 0.13)
    adjusted HR (95% CI; P)bc0.79 (0.46 to 1.38; 0.41)
    adjusted HR (95% CI; P)b with PF4-H-ABs as continuous variable0.85 (0.54 to 1.32; 0.46)
MI
    no. of events during study16336
    Kaplan-Meier estimate (95% CI)a0.22 (0.19 to 0.25)0.23 (0.15 to 0.31)
    adjusted HR (95% CI; P)bc1.03 (0.71 to 1.48; 0.89)
    adjusted HR (95% CI; P)b with PF4-H-ABs as continuous variable0.97 (0.72 to 1.30; 0.81)
  • a Unadjusted Kaplan-Meier estimates at the end of year 4.

  • b Explanatory variables were selected by a stepwise process with adjustment for treatment assignment (was always included in the final model), gender, age, phosphate, LDL, hemoglobin, glycated hemoglobin, CRP, ever smoked, systolic and diastolic BP, body mass index, ultrafiltration volume, duration of dialysis, hemodialysis shunt, history of stroke/transient ischemic attack, coronary artery disease (MI, coronary artery bypass grafting, percutaneous coronary intervention, and angiographically documented coronary artery disease), arrhythmia, peripheral vascular disease, and congestive heart failure (predominantly New York Heart Association class II).

  • c Patients with negative PF4-H-AB status (OD <0.4) at baseline served as the reference.